The purpose of this study is to determine whether treatment with Blinatumomab is effective in reducing the risk of acute lymphoblastic leukemia returning in patients with residual cancer cells remaining in the body after stem cell transplant.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.